Janssen Biotech Inc.

30/07/2024 | Press release | Archived content

DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant eligible